Literature DB >> 6861318

Effect of hydralazine on perfusion and metabolism in the leg during upright bicycle exercise in patients with heart failure.

J R Wilson, J L Martin, N Ferraro, K T Weber.   

Abstract

The aerobic exercise capacity of patients with chronic heart failure is frequently impaired because of inadequate O2 transport to working skeletal muscle. To determine whether hydralazine improves O2 transport to working muscle, we examined the effect of intravenous hydralazine on blood flow (measured by thermodilution) and metabolism in the leg during maximal upright bicycle exercise in 10 patients with chronic heart failure. Hydralazine increased maximal exercise cardiac output (5.6 +/- 0.7 to 6.7 +/- 0.6 l/min; p less than .01) and decreased systemic O2 extraction (79 +/- 3% to 65 +/- 2%; p less than .01) but did not alter maximal O2 uptake (787 +/- 105 vs 779 +/- 82 ml/min). Leg blood flow at maximal exercise increased from 1.6 +/- 0.2 to 2.1 +/- 0.4 l/min (p less than .03); the proportion of cardiac output delivered to the leg remained unchanged (59 +/- 3% vs 57 +/- 9%). This increase in flow was associated with a decrease in O2 extraction in the leg (84 +/- 2% to 79 +/- 2%; p less than .01) and no change in peak femoral venous lactate (59.1 +/- 7.4 vs 54.1 +/- 5.3 mg/dl), suggesting that there is functional or anatomic shunting of the augmented limb flow rather than delivery to metabolizing muscle. These data suggest that hydralazine augments flow to the exercising limb in patients with heart failure but that this augmented flow does not increase oxygen availability within working muscle.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6861318     DOI: 10.1161/01.cir.68.2.425

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  17 in total

Review 1.  Peripheral limitations of maximal aerobic capacity in patients with chronic heart failure.

Authors:  Stuart D Katz; Haoyi Zheng
Journal:  J Nucl Cardiol       Date:  2002 Mar-Apr       Impact factor: 5.952

2.  Endothelial control of lower limb blood flow in chronic heart failure.

Authors:  D C Lindsay; D R Holdright; D Clarke; I S Anand; P A Poole-Wilson; P Collins
Journal:  Heart       Date:  1996-05       Impact factor: 5.994

3.  Hemodynamic responses to small muscle mass exercise in heart failure patients with reduced ejection fraction.

Authors:  Zachary Barrett-O'Keefe; Joshua F Lee; Amanda Berbert; Melissa A H Witman; Jose Nativi-Nicolau; Josef Stehlik; Russell S Richardson; D Walter Wray
Journal:  Am J Physiol Heart Circ Physiol       Date:  2014-09-26       Impact factor: 4.733

Review 4.  Peripheral circulatory adaptations to pump failure of the heart.

Authors:  H Drexler
Journal:  Br Heart J       Date:  1994-08

5.  Analysis of Skeletal Muscle Torque Capacity and Circulating Ceramides in Patients with Advanced Heart Failure.

Authors:  Danielle L Brunjes; Mark Dunlop; Christina Wu; Meaghan Jones; Tomoko S Kato; Peter J Kennel; Hilary F Armstrong; Tse-Hwei Choo; Matthew N Bartels; Daniel E Forman; Donna M Mancini; P Christian Schulze
Journal:  J Card Fail       Date:  2016-02-12       Impact factor: 5.712

6.  Modifications of skeletal muscle ryanodine receptor type 1 and exercise intolerance in heart failure.

Authors:  Eric Rullman; Daniel C Andersson; Michael Melin; Steven Reiken; Donna M Mancini; Andrew R Marks; Lars H Lund; Thomas Gustafsson
Journal:  J Heart Lung Transplant       Date:  2013-09       Impact factor: 10.247

7.  Abnormalities of skeletal muscle metabolism in patients with chronic heart failure: evidence that they are present at rest.

Authors:  R Andrews; J T Walsh; A Evans; S Curtis; A J Cowley
Journal:  Heart       Date:  1997-02       Impact factor: 5.994

Review 8.  Implications of chronic heart failure on peripheral vasculature and skeletal muscle before and after exercise training.

Authors:  Brian D Duscha; P Christian Schulze; Jennifer L Robbins; Daniel E Forman
Journal:  Heart Fail Rev       Date:  2008-02       Impact factor: 4.214

Review 9.  Newer positive inotropic agents in the treatment of chronic cardiac failure. Current status and future directions.

Authors:  K T Weber; S K Gill; J S Janicki; C S Maskin; M C Jain
Journal:  Drugs       Date:  1987-05       Impact factor: 9.546

10.  Chronic heart failure and exercise intolerance: the hemodynamic paradox.

Authors:  Kent R Nilsson; Brian D Duscha; Patrick M Hranitzky; William E Kraus
Journal:  Curr Cardiol Rev       Date:  2008-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.